甲氧苯甲酰水飞蓟宾用于制备治疗病毒性乙肝药物的用途

Application of methoxybenzene benzoyl silibinin in preparing medicine for treating viral hepatitis B

Abstract

本发明涉及甲氧苯甲酰水飞蓟宾用于制备治疗病毒性乙肝药物的用途,具体而言,本发明涉及一个23位4-甲氧基苯甲酰基取代的水飞蓟宾酯型黄酮木脂素或其可药用盐用于制备抑制HBV DNA复制、治疗乙型肝炎病毒感染疾病药物的用途,该黄酮木脂素具有确切抑制乙肝病毒HBV DNA活性,其在100微克/毫升时对乙肝病毒HBV DNA的复制抑制活性优于α-干扰素在最高浓度10000单位/毫升浓度时的抑制活性(高出47%),以上药效学结果表明该黄酮木脂素或其可药用盐可预期用于制备非核苷类抑制HBV DNA复制或治疗乙型肝炎病毒感染疾病药物的用途。
The invention relates to an application of methoxybenzene benzoyl silibinin in preparing medicine for treating viral hepatitis B, in particular relates to an application of a silibinin esterified favonolignan compound substituted by 23-site 4-metoxybenzene benzoyl, or pharmaceutically acceptable salt thereof in preparing medicines for inhibiting HBV DNA replication, and treating hepatitis B virus infection diseases, wherein the favonolignan compound has exact inhibition activity to the hepatitis B virus, the inhibition activity thereof at 100 microgramme/mL to the HBV DNA replication of the hepatitis B virus is better than that of the alpha-interferon at the highest concentration of 10000 uint/mL, namely 47% higher than that of the inhibition activity of the alpha-interferon. The pharmacodynamics results show that the favonolignan compound or the pharmaceutically acceptable salt thereof can be expected to be used for preparing the medicine for inhibiting non-nucleoside HBV DNA replication or treating the hepatitis B virus infection diseases.

Claims

Description

Topics

Download Full PDF Version (Non-Commercial Use)

Patent Citations (1)

    Publication numberPublication dateAssigneeTitle
    CN-1990484-AJuly 04, 2007浙江海正天华新药研发有限公司Silybin esters derivatives and preparation and use thereof

NO-Patent Citations (0)

    Title

Cited By (0)

    Publication numberPublication dateAssigneeTitle